 SOUTH SAN FRANCISCO, Calif., April 21, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced that the U.S. Food and Drug Administration FDA granted Regenerative Medicine Advanced Therapy RMAT designation to ALLO-715 in relapsedrefractory multiple myeloma. The FDA granted RMAT designation based on the potential of ALLO-715 to address the growing unmet need for patients who have failed other multiple myeloma therapies. 